Related Experiment Video
Updated: Feb 27, 2026
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
[Clinical Significance of Mean Platelet Volume Determination in Multiple Myeloma]
Peng Gao1, Zhong-Ping Xiao1, Kun Fu1
1Department of Hematology, Jilin Province People's Hospital, Changchun 130021, Jilin Province, China.
Objective:
To investigate the clinical significance of mean platelet volume(MPV) in patients with multiple myeloma(MM).
Methods:
The clinical data of 198 patients with MM admitted in our hospital from March 2008 to March 2015 were collected and analyzed. The clinical data included the Ig type, hemoglobin level, platelet count, creatinine, calciumion albumin, β2-MG, LDH, plasmocytes in bone marrow, MPV, complications such as diabetes, a history of venous thromboembolism (VTE) and arterial events such as coronary artery disease, cerebrovascular disease, thrombosis and blood clotting. All patients were divided into low MPV group (≤8.50 fl) and high MPV group (>8.50 fl). The biochemical parameters and prognosis of the 2 groups were compared.
Results:
When MPV was 8.50 fl, the higest sensitivety and specificity were 55.56% and 80.00% respectively. The area under curve (AUC) was 0.656 (95% CI: 0.515-0.797), the IgA type, creatinine level and IgH rearrangement in MM patients were related with MPV. The ratio of IgA and IgH rearrangements in patients with low MPV was higher than that in patients with high MPV, and the ratio of patients with creatinine >176.8 µmol/L was lower than that of patients with high MPV (P<0.05). The age, sex, ECOG PS, complications, ISS stage, hemoglobin level, platelet count, calcium ion, albumin, β2 microglobulin, lactate dehydrogenase and bone marrow plasma cell ratio were not statistically significantly different between the 2 groups. Patients with low MPV had a shorter OS (P=0.039) than those with higher MPV. Univariate analysis showed that MPV, BM plasma cell ratio and age>60 years correleted with OS. Multivariate analysis showed that the low MPV and BM plasma cell ratio were correlated with shorter OS (P<0.05).
Conclusion:
The low MPV is correlated with poor prognosis in patients with MM and may serve as an important indicator for disease progression and prognosis of patients with MM.
Insights
Low mean platelet volume (MPV) indicates a poorer prognosis in multiple myeloma (MM) patients. This finding suggests MPV can be a valuable indicator for monitoring disease progression and predicting outcomes in MM.
Area of Science:
- Hematology
- Oncology
Background:
- Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled plasma cell proliferation.
- Mean platelet volume (MPV) is a measure of platelet size and activation, and its role in various diseases is increasingly recognized.
Purpose of the Study:
- To investigate the clinical significance and prognostic value of mean platelet volume (MPV) in patients diagnosed with multiple myeloma (MM).
Main Methods:
- A retrospective analysis of clinical data from 198 multiple myeloma patients was conducted.
- Patients were categorized into low MPV (≤8.50 fl) and high MPV (>8.50 fl) groups for comparison.
- Clinical parameters, including Ig type, creatinine, and overall survival (OS), were analyzed in relation to MPV levels.
Main Results:
- Low MPV was associated with IgA type and higher creatinine levels in MM patients.
- Patients with low MPV exhibited a significantly shorter overall survival (OS) compared to those with high MPV (P=0.039).
- Multivariate analysis identified low MPV and high bone marrow plasma cell ratio as independent predictors of shorter OS.
Conclusions:
- Mean platelet volume (MPV) is a significant prognostic factor in multiple myeloma (MM).
- Lower MPV levels correlate with a poorer prognosis and shorter survival in MM patients.
- MPV may serve as a valuable, easily accessible biomarker for assessing disease progression and predicting outcomes in MM.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015